Cargando…
糖皮质激素对免疫检查点抑制剂疗效影响的研究进展
Immune checkpoint inhibitors (ICIs), including programmed death receptor-1 (PD-1)/ligand (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody, have been approved for the treatment of multiple advanced malignant tumors, on account of its ideal antitumor activity. For p...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935042/ https://www.ncbi.nlm.nih.gov/pubmed/31874675 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.12.09 |